AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteGLPG0634 is an orally-available, selective inhibitor of JAK1 (Janus kinase 1) being developed by Galapagos for the treatment of rheumatoid arthritis and potentially other inflammatory diseases.
More Information Supplier PageGLPG0634 is an orally-available, selective inhibitor of JAK1 (Janus kinase 1) being developed by Galapagos for the treatment of rheumatoid arthritis and potentially other inflammatory diseases.
More Information Supplier PageGly-Phe-beta-naphthylamide is a cathepsin C substrate. The compound is described to accumulate inside lysosomes leading to their destruction.
More Information Supplier PageGly-Phe-beta-naphthylamide is a cathepsin C substrate. The compound is described to accumulate inside lysosomes leading to their destruction.
More Information Supplier PageGly-Phe-beta-naphthylamide is a cathepsin C substrate. The compound is described to accumulate inside lysosomes leading to their destruction.
More Information Supplier PageGlycitein is an O-methylated isoflavone which accounts for 5-10% of the total isoflavones in soy food products.
More Information Supplier PageGlycitein is an O-methylated isoflavone which accounts for 5-10% of the total isoflavones in soy food products.
More Information Supplier PageGlycitin is a natural isoflavone isolated from legumes, including soy and kudzu.
More Information Supplier PageGlycitin is a natural isoflavone isolated from legumes, including soy and kudzu.
More Information Supplier PageGlycyl-H 1152 2HCl is a selective and potent ROCK inhibitor (IC50 values are 0.0118, 2.35, 2.57, 3.26, > 10 and >10 uM for ROCKII, Aurora A, CAMKII, PKG, PKA and PKC respectively.)
More Information Supplier PageGlycyl-H 1152 2HCl is a selective and potent ROCK inhibitor (IC50 values are 0.0118, 2.35, 2.57, 3.26, > 10 and >10 uM for ROCKII, Aurora A, CAMKII, PKG, PKA and PKC respectively.)
More Information Supplier PageGlycyl-H 1152 2HCl is a selective and potent ROCK inhibitor (IC50 values are 0.0118, 2.35, 2.57, 3.26, > 10 and >10 uM for ROCKII, Aurora A, CAMKII, PKG, PKA and PKC respectively.)
More Information Supplier PageGlycyrrhetinic acid inhibits the enzymes (15-hydroxyprostaglandin dehydrogenase and delta-13-prostaglandin) that metabolize the prostaglandins PGE-2 and PGF-2?? to their respective 15-keto-13,14-dihydro metabolites which are inactive.
More Information Supplier PageGlycyrrhetinic acid inhibits the enzymes (15-hydroxyprostaglandin dehydrogenase and delta-13-prostaglandin) that metabolize the prostaglandins PGE-2 and PGF-2?? to their respective 15-keto-13,14-dihydro metabolites which are inactive.
More Information Supplier PageGlycyrrhetinic acid inhibits the enzymes (15-hydroxyprostaglandin dehydrogenase and delta-13-prostaglandin) that metabolize the prostaglandins PGE-2 and PGF-2?? to their respective 15-keto-13,14-dihydro metabolites which are inactive.
More Information Supplier PageGlycyrrhizic acid is a widely used anti-inflammatory agent isolated from the licorice root.
More Information Supplier PageGlycyrrhizic acid is a widely used anti-inflammatory agent isolated from the licorice root.
More Information Supplier PageGlycyrrhizic acid is a widely used anti-inflammatory agent isolated from the licorice root.
More Information Supplier PageGlycyrrhizic acid is a widely used anti-inflammatory agent isolated from the licorice root.
More Information Supplier PageGlycyrrhizic acid is a widely used anti-inflammatory agent isolated from the licorice root.
More Information Supplier PageGLYX-13 is a selective weak partial agonist of the glycine site of the NMDA receptor (IA ?? 25%) which is under development by Naurex as an adjunctive therapy for treatment-resistant depression.
More Information Supplier PageGLYX-13 is a selective weak partial agonist of the glycine site of the NMDA receptor (IA ?? 25%) which is under development by Naurex as an adjunctive therapy for treatment-resistant depression.
More Information Supplier PageGLYX-13 is a selective weak partial agonist of the glycine site of the NMDA receptor (IA ?? 25%) which is under development by Naurex as an adjunctive therapy for treatment-resistant depression.
More Information Supplier PageGM 6001 is a potent, reversible broad spectrum inhibitor of zinc-containing proteases, including matrix metalloproteinases (MMPs).
More Information Supplier PageGM 6001 is a potent, reversible broad spectrum inhibitor of zinc-containing proteases, including matrix metalloproteinases (MMPs).
More Information Supplier PageGM 6001 is a potent, reversible broad spectrum inhibitor of zinc-containing proteases, including matrix metalloproteinases (MMPs).
More Information Supplier PageGM 6001 is a potent, reversible broad spectrum inhibitor of zinc-containing proteases, including matrix metalloproteinases (MMPs).
More Information Supplier PageGNE-493 is potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitor with potential anticancer activity.
More Information Supplier PageGNE-493 is potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitor with potential anticancer activity.
More Information Supplier PageGNE-493 is potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitor with potential anticancer activity.
More Information Supplier PageGNE-7915 is a Blood-Brain Barrier (BBB) penetrable small molecule inhibitor of Leucine-Rich Repeat Kinase 2 (LRRK2).
More Information Supplier PageGNE-7915 is a Blood-Brain Barrier (BBB) penetrable small molecule inhibitor of Leucine-Rich Repeat Kinase 2 (LRRK2).
More Information Supplier PageGNE-7915 is a Blood-Brain Barrier (BBB) penetrable small molecule inhibitor of Leucine-Rich Repeat Kinase 2 (LRRK2).
More Information Supplier Page
